Bio-Thera Kicks Off Ustekinumab Trial
Phase I Study Follows Similar Efforts From Rival Stelara Biosimilars
China’s Bio-Thera solutions has announced the start of Phase I trials for its ustekinumab biosimilar. The project is one among several potential rivals to Stelara in the works from a host of developers.
You may also be interested in...
Bio-Thera Conducts Simponi Phase III Trial
China’s Bio-Thera Solutions has announced the start of Phase III trials for its BAT2506 proposed biosimilar golimumab rival to Janssen’s Simponi.
BioFactura Joins Stelara Biosimilar Crowd
Janssen’s Stelara is continuing to attract a growing crowd of proposed biosimilar rivals, with BioFactura becoming the latest to throw its hat into the ring after kicking off Phase I trials for its BFI-751 version.
Meiji Seika Is Latest To Kick Off Ustekinumab Phase III
Meiji Seika and Dong-A Socio Holdings have become the latest developers to announce the start of Phase III trials for an ustekinumab biosimilar rival to Stelara.